Immunological biomarkers predict HIV-1 viral rebound after treatment interruption
Citations Over TimeTop 10% of 2015 papers
Abstract
Treatment of HIV-1 infection with antiretroviral therapy (ART) in the weeks following transmission may induce a state of 'post-treatment control' (PTC) in some patients, in whom viraemia remains undetectable when ART is stopped. Explaining PTC could help our understanding of the processes that maintain viral persistence. Here we show that immunological biomarkers can predict time to viral rebound after stopping ART by analysing data from a randomized study of primary HIV-1 infection incorporating a treatment interruption (TI) after 48 weeks of ART (the SPARTAC trial). T-cell exhaustion markers PD-1, Tim-3 and Lag-3 measured prior to ART strongly predict time to the return of viraemia. These data indicate that T-cell exhaustion markers may identify those latently infected cells with a higher proclivity to viral transcription. Our results may open new avenues for understanding the mechanisms underlying PTC, and eventually HIV-1 eradication.
Related Papers
- → Transient Viremia, Plasma Viral Load, and Reservoir Replenishment in HIV-Infected Patients on Antiretroviral Therapy(2007)115 cited
- → Viral load assay sensitivity and low level viremia in HAART treated HIV patients(2010)28 cited
- → More than ten years without any detectable HIV viremia: exceptionally long-term non-progressive HIV infection(2010)1 cited
- → Faculty Opinions recommendation of Treatment intensification does not reduce residual HIV-1 viremia in patients on highly active antiretroviral therapy.(2009)
- → Maintenance of antiretroviral therapy despite low-level viremia in HIV patients appears to be appropriate(2004)